Reaction Details Report a problem with these data
Target
Kallikrein-1
Ligand
BDBM528077
Substrate
n/a
Meas. Tech.
Determination of the IC50 for KLK1
IC50
>4000±n/a nM
Citation
 Davie, RL; Edwards, HJ; Evans, DM; Hodgson, ST; Pethen, SJ; Rooker, DP Pyrazole derivatives as plasma kallikrein inhibitors US Patent  US11180484 Publication Date 11/23/2021 
Target
Name:
Kallikrein-1
Synonyms:
Kallikrein-1 | Kidney/pancreas/salivary gland kallikrein | Tissue kallikrein | KLK1_HUMAN | KLK1 | Kallikrein 1
Type:
Enzyme
Mol. Mass.:
28874.69
Organism:
Human
Description:
P06870
Residue:
262
Sequence:
MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWVLTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHDLMLLRLTEPADTITDAVKVVELPTEEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKILPNDECKKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNKPSVAVRVLSYVKWIEDTIAENS
  
Inhibitor
Name:
BDBM528077
Synonyms:
N-i6-chloro-2-fluoro-3-methoxybenzyl)-1 -ii2-methylquinolin-6-yl)methyl)-1 H-1 ,2,3-triazole-4-carboxamide | US11180484, Example 14 from WO 013/111108
Type:
Small organic molecule
Emp. Form.:
n/a
Mol. Mass.:
n/a
SMILES:
COc1ccc(Cl)c(CNC(=O)c2cn(Cc3ccc4nc(C)ccc4c3)nn2)c1F
Structure:
Search PDB for entries with ligand similarity: